Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia.

Frontiers in immunology 2023

filter terms:

The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific T cell engager (BiTE) therapy to manage myeloid malignancies has proven more challenging than for B-cell malignancies. This is attributed to a shortage of leukemia-specific cell-surface antigens that distinguish healthy from malignant myeloid populations, and the inability to manage myeloid depletion unlike B-cell aplasia. Therefore, the development of targeted therapeutics for myeloid malignancies, such as acute myeloid leukemia (AML), requires new approaches. Herein, we developed a ligand-based CAR and secreted bi-specific T cell engager (sBite) to target c-kit using its cognate ligand, stem cell factor (SCF). c-kit is highly expressed on AML blasts and correlates with resistance to chemotherapy and poor prognosis, making it an ideal candidate for which to develop targeted therapeutics. We utilize γδ T cells as a cytotoxic alternative to αβ T cells and a transient transfection system as both a safety precaution and switch to remove alloreactive modified cells that may hinder successful transplant. Additionally, the use of γδ T cells permits its use as an allogeneic, off-the-shelf therapeutic. To this end, we show mSCF CAR- and hSCF sBite-modified γδ T cells are proficient in killing c-kit+ AML cell lines and sca-1+ murine bone marrow cells in vitro. In vivo, hSCF sBite-modified γδ T cells moderately extend survival of NSG mice engrafted with disseminated AML, but therapeutic efficacy is limited by lack of γδ T-cell homing to murine bone marrow. Together, these data demonstrate preclinical efficacy and support further investigation of SCF-based γδ T-cell therapeutics for the treatment of myeloid malignancies. Copyright © 2023 Branella, Lee, Okalova, Parwani, Alexander, Arthuzo, Fedanov, Yu, McCarty, Brown, Chandrakasan, Petrich, Doering and Spencer.

Citation

Gianna M Branella, Jasmine Y Lee, Jennifer Okalova, Kiran K Parwani, Jordan S Alexander, Raquel F Arthuzo, Andrew Fedanov, Bing Yu, David McCarty, Harrison C Brown, Shanmuganathan Chandrakasan, Brian G Petrich, Christopher B Doering, H Trent Spencer. Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia. Frontiers in immunology. 2023;14:1294555